You really seemed focused on those B shares. You really don't seem to understand why they were issued, and specifically, what they are being used for. Its a shame that someone as smart as you are cannot recognize that there are other smart people who understand how to build overall value for a public company within the confines of regulatory restrictions in the public markets. I think you have been trading in OTC companies for too long. You see it as a dilution against the shareholder base, whereas I am sure, future news and disclosures will prove otherwise to you, yet I believe you would never give anyone else credit unless you were the one that came up with the plan.
But you would first have to start with the presumption that this isn't a typical OTC company nor is it being structured as one, so I would start researching insider stock structures/transactions in companies that get $10 - 100M in equity financing that trade NASDAQ and NYSE. Then, you could look at some big investment banking deals, via other public companies disclosures, to see how the bankers wanted new offering deals structured, especially where insiders hold a majority, or convertible majority position.
I will be amazed if your come-back is other than accusatory or critical.
